Role of neutrophils in cutaneous lupus erythematosus.
NETs
lupus erythematosus
plasmacytoid dendritic cell
type I interferon
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
revised:
24
10
2023
received:
12
10
2023
accepted:
27
10
2023
medline:
27
11
2023
pubmed:
27
11
2023
entrez:
27
11
2023
Statut:
aheadofprint
Résumé
There are various types of cutaneous lupus erythematosus (CLE), either with or without the association of systemic lupus erythematosus (SLE). In some of the subtypes of cutaneous lupus, histopathology reveals neutrophil infiltration in the lesional skin; however, the significance of neutrophils in CLE is not yet fully elucidated. Recent studies have shown that neutrophil extracellular traps (NETs) formation by activated neutrophils is observed in several types of CLE, including lupus panniculitis, subacute lupus erythematosus, and acute lupus erythematosus, although the number of reports is small. Excessive NETosis, due to either increased NETs formation or defective clearance of NETs, may play a role in the induction of autoimmunity and autoantibody production in SLE, as well as endothelial damage, thrombus formation, and vascular damage in the lesional skin. CLE is an excessive interferon-driven autoimmune disease. Plasmacytoid dendritic cells are located in lupus erythematosus skin and contribute to the etiology of skin lesions as a main producing cell of type I interferon. Neutrophils, monocytes, and keratinocytes also produce type I interferon via several triggers. Neutrophils play an important role in the innate immune response in SLE. In this review, several types of CLE with neutrophil infiltration, as well as the role of neutrophils are discussed.
Identifiants
pubmed: 38009863
doi: 10.1111/1346-8138.17036
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Japanese Dermatological Association.
Références
Wysenbeek AJ, Guedj D, Amit M, Weinberger A. Rash in systemic lupus erythematosus: prevalence and relation to cutaneous and non-cutaneous disease manifestations. Ann Rheum Dis. 1992;51:717-719.
Tebbe B, Orfanos CE. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus. 1997;6:96-104.
Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159:237-243.
Maz M, Martens JWS, Hannoudi A, et al. Recent advances in cutaneous lupus. J Autoimmun. 2022;132:102865.
Lipsker D, Saurat JH. Neutrophilic cutaneous lupus erythematosus: at the edge between innate and acquired immunity? Dermatology. 2008;216:283-286.
Crow MK. Advances in understanding the role of type I interferons in systemic lupus erythematosus. Curr Opin Rheumatol. 2014;26:467-474.
Fernandez-Ruiz R, Niewold TB. Type I interferons in autoimmunity. J Invest Dermatol. 2022;142:793-803.
Nakabo S, Romo-Tena J, Kaplan MJ. Neutrophils as drivers of immune dysregulation in autoimmune diseases with skin manifestations. J Invest Dermatol. 2022;142:823-833.
Tsai CY, Li KJ, Hsieh SC, Liao HT, Yu CL. What's wrong with neutrophils in lupus? Clin Exp Rheumatol. 2019;37:684-693.
Romo-Tena J, Kaplan MJ. Immunometabolism in the pathogenesis of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2020;32:562-571.
Leffler J, Gullstrand B, Jonsen A, et al. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther. 2013;15:R84.
Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564-569.
Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3:73ra20.
Ma S, Jiang W, Zhang X, Liu W. Insights into the pathogenic role of neutrophils in systemic lupus erythematosus. Curr Opin Rheumatol. 2023;35:82-88.
Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine. 2009;88:23-31.
Pavlidakey P, Mills O, Bradley S, Casey J, Morgan MB. Neutrophilic dermatosis revisited: as initial presentation of lupus? J Am Acad Dermatol. 2012;67:e29-e35.
Gusdorf L, Bessis D, Lipsker D. Lupus erythematosus and neutrophilic urticarial dermatosis: a retrospective study of 7 patients. Medicine. 2014;93:e351.
Larson AR, Granter SR. Systemic lupus erythematosus-associated neutrophilic dermatosis: an underrecognized neutrophilic dermatosis in patients with systemic lupus erythematosus. Human Pathol. 2014;45:598-605.
Contestable JJ, Edhegard KD, Meyerle JH. Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment. Am J Clin Dermatol. 2014;15:517-524.
Hanami Y, Mori T, Yamamoto T. Ulceration in lupus erythematosus profundus unassociated with vasculitis: report of three cases. Indian J Dermatol. 2023;68:235.
Miyashita A, Fukushima S, Makino T, Yoshino Y, Yamashita J, Honda N, et al. The proportion of lymphocytic inflammation with CD123-positive cells in lupus erythematosus profundus predict a clinical response to treatment. Acta Derm Venereol. 2014;94:563-567.
Chen SJT, Tse JY, Harms PW, Hristov AC, Chan MP. Utility of CD123 immunohistochemistry in differentiating lupus erythematosus from cutaneous T cell lymphoma. Histopathology. 2019;74:908-916.
Marzano AV, Ramoni S, Caputo R. Amicrobial pustulosis of the folds: report of 6 cases and a literature review. Dermatology. 2008;216:305-311.
Facheris P, De Santis M, Gargiulo L, et al. Concomitant pyoderma gangrenosum-like and amicrobial pustulosis of the folds: a case report. J Clin Immunol. 2020;40:1038-1040.
Zirwas M, Dobkin HE, Krishnamurthy S. Amicrobial pustulosis of the folds and palmoplantar pustulosis simultaneously induced by different tumor necrosis factor-α inhibitors: demonstration of a shared pathophysiology. JAAD Case Rep. 2017;30:401-403.
Liu Y, Kaplan MJ. Neutrophils in the pathogenesis of rheumatic diseases: fueling the fire. Clin Rev Allegy Immunol. 2021;60:1-16.
Fu X, Liu H, Huang G, Dai SS. The emerging role of neutrophils in autoimmune-associated disorders: effector, predictor, and therapeutic targets. MedComm. 2021;2:402-413.
Guiducci C, Tripodo C, Gong M, Sangaletti S, Colombo MP, Coffman RL, et al. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med. 2010;207:2931-2942.
Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol. 2011;187:538-552.
Safi R, Al-Hage J, Abbas O, et al. Investigating the presence of neutrophil extracellular traps in cutaneous lesions of different subtypes of lupus erythematosus. Exp Dermatol. 2019;28:1348-1352.
Dong H, Hao Y, Li W, Yang W, Gao P. IL-36 cytokines: their roles in asthma and potential as a therapeutic. Front Immunol. 2022;13:921275.
Macleod T, Doble R, McGonagle D, Wasson CW, Alase A, Stacey M, et al. Neutrophil elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 receptor antagonist. Sci Rep. 2016;6:24880.
Henry CM, Sullivan GP, Clancy DM, Afonina IS, Kulms D, Martin SJ. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep. 2016;14:708-722.
Georgakis S, Gkirtzimanaki K, Papadaki G, Gakiopoulou H, Drakos E, Eloranta ML, et al. NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-α production in patients with SLE. JCI Insight. 2021;6:e147671.
Bruschi M, Moroni G, Sinico RA, Franceschini F, Fredi M, Vaglio A, et al. Neutrophil extracellular traps in the autoimmunity context. Front Med. 2021;8:614829.
Asselin-Paturel C, Brizard G, Chemin K, et al. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med. 2005;201:1157-1167.
Psarras A, Alase A, Antanaviciute A, Carr IM, Md Yusof MY, Wittmann M, et al. Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. Nat Commun. 2020;11:6149.
O'Brien JC, Hosler GA, Chong BF. Changes in T cell and B cell composition in discoid lupus erythematosus skin at different stages. J Dermatol Sci. 2017;85:247-249.
Wenzel J, Landmann A, Vorwerk G, Kuhn A. High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus. Exp Dermatol. 2018;27:95-97.
Tsokos G, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12:716-730.
Jenks S, Wei C, Bugrovsky R, et al. B cell subset composition segments clinically and serologically distinct groups in chronic cutaneous lupus erythematosus. Ann Rheum Dis. 2021;80:1190-1200.
Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:155-166.
Marketos N, Cinoku I, Rapti A, Mavragani CP. Type I interferon signature in Sjögren's syndrome: pathophysiological and clinical implications. Clin Exp Rheumatol. 2019;37(Suppl 118):S185-S191.
Werth VP, Romero-Diaz FJ, Kalunian NK, et al. Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N Engl J Med. 2022;387:321-331.
Smith N, Rodero MP, Bekaddour N, Bondet V, Ruiz-Blanco YB, Harms M, et al. Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement: a new target for lupus treatment. Sci Adv. 2019;5:eaav9019.
Jiang J, Zhao M, Chang C, Wu H, Lu Q. Type I interferons in the pathogenesis and treatment of autoimmune diseases. Clin Rev Allergy Immunol. 2020;59:248-272.